IL2 and melanoma: In melanoma, the antitumor activity of the hu14.18-IL2 immunocytokine was evaluated in a minimal residual disease setting (NCT00590824), and prolonged tumor-free survival was seen in some treated melanoma patients at risk of recurrence [46].